VUZI 241220 4.00C (VUZI241220C4000) Stock Options, News & Quotes

0.05
+0.01+25.00%

15min DelayClose Nov 27 16:00 ET

0.10High0.05Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Daily Investors

1 hour ago

VUZI

Despite being negative, it has strong mid to long term signals. Expecting to have another major news article this week, about their progress.

ahhh_shicha__yabicha

20 hours ago

$Vuzix (VUZI.US)$ VUZI like two others I am holding ( $Archer Aviation (ACHR.US)$ and $Joby Aviation (JOBY.US)$ ) are beginning to show hints of future profitability, have begun the initial stages of short covering, and have potentials for squeeze. Per Short squeeze.com, Vuzix is the most significant with 16.4 million short shares out of 61 million free float. This is a ridiculously high of 27% 39 DTC, days to cover!
I've been in the market many many years and these types of stocks are ofte...

Trytosaveabit

Nov 26 07:11

Update

$Vuzix (VUZI.US)$ Vuzix to Showcase Full Color, State-of-the-Art, See-Through, Waveguide-Based Smart Glasses Designs at Upcoming CES 2025 Event
3 minutes ago, 8:07 AM EST
Via PR Newswire

Jaguar8

Nov 26 07:09

NEWS

$Vuzix (VUZI.US)$
Vuzix to Showcase Full Color, State-of-the-Art, See-Through, Waveguide-Based Smart Glasses Designs at Upcoming CES 2025 Event
Vuzix (NASDAQ: VUZI) has announced its participation in CES 2025 (January 7-10, 2024) where it will showcase new waveguide technologies and smart glasses designs. The company will display its new full-color 1.0mm thin waveguideand a super-slim 0.7mm waveguide, alongside various display engines including µLEDs and LCoS projectors. Multiple new OEM Ul...

Jaguar8

Nov 25 22:28

MY WATCHLIST TUESDAY (November 26). Trade the Chart. Don’t open position impulsively.

I WILL UPDATE IF I FIND MORE
$Poseida Therapeutics (PSTX.US)$ ✔️TOP PLAY. To be acquired by Roche for $1.5B for $9.00/share. “Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash”
$Citius Pharmaceuticals (CTXR.US)$✔️ News halt after hours + PR today o...

Bitcoin ups and downs: How far is it from $100,000?